Skip navigation

Drugmaker Vivus settles with biggest shareholder

Obesity drugmaker Vivus has agreed to a settlement with its biggest shareholder, which has been fighting for greater control of the company. A long-time drug executive backed by the shareholder will become CEO and the board will be reconfigured. Full story

AstraZeneca finance chief Lowth to quit for BG Group

LONDON (Reuters) - Simon Lowth is to quit as chief financial officer at AstraZeneca and return to his energy roots in the same role at BG Group after being passed over for the top job at the drugmaker. Full story

AstraZeneca signs up first Cambridge partners in cancer research

LONDON (Reuters) - British pharmaceutical company AstraZeneca has agreed its first research partnerships in Cambridge for cancer treatments ahead of its relocation to the university city by 2016. Full story

$1.5 Billion in DoD Contracts Includes Flu Vaccines and New Shirts

AstraZeneca subsidiary MedImmune Biologics won a contract to supply influenza vaccine doses deliverable by nasal spray. Full story

AstraZeneca turnaround is three-four year journey, says CEO

LONDON (Reuters) - Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday. Full story

AstraZeneca taps outside experts to screen cancer compounds

LONDON (Reuters) - British drugmaker AstraZeneca is deepening its collaboration with academia by roping in more outside researchers to help to find new cancer drugs. Full story

Sponsored Links

Articles

AstraZeneca buys U.S. lung drug firm Pearl for up to $1.15 billion

AstraZeneca closes in on site for new home in Cambridge

AstraZeneca's new strategy gets thumbs down from S&P

AstraZeneca suffers fresh drug patent setback in U.S

AstraZeneca CEO says exploring biosimilars market

AstraZeneca to axe 1,600 jobs in major R&D overhaul

U.S. appeals court finds Astra's Seroquel XR patent infringed

Related Photos

The CEO of AstraZeneca, Pascal Soriot, is seen posing for a photograph in this undated picture provided by AstraZeneca in London
The CEO of AstraZeneca, Pascal Soriot, is seen posing for a photograph in this undated picture provided by AstraZeneca in London

The Chief Executive Officer of AstraZeneca, Pascal Soriot, is seen posing for a photograph in this undated picture provided by AstraZeneca in London on March 12, 2013. REUTERS/Marcus Lyon/AstraZeneca/Handout

Chief Executive Officer of AstraZeneca Pascal Soriot poses for a photograph in this undated picture provided by AstraZeneca in London
Chief Executive Officer of AstraZeneca Pascal Soriot poses for a photograph in this undated picture provided by AstraZeneca in London

Chief Executive Officer of AstraZeneca Pascal Soriot poses for a photograph in this undated picture provided by AstraZeneca in London on March 12, 2013. REUTERS/Marcus Lyon/AstraZeneca/Handout/Files

CEO of AstraZeneca, Pascal Soriot, poses for a photograph in this undated picture provided by AstraZeneca in London
CEO of AstraZeneca, Pascal Soriot, poses for a photograph in this undated picture provided by AstraZeneca in London

Chief Executive Officer of AstraZeneca, Pascal Soriot, poses for a photograph in this undated picture provided by AstraZeneca in London on March 12, 2013. REUTERS/Marcus Lyon/AstraZeneca/Handout/Files